Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study

Sandeep Mukherjee, R. K. Gilroy, T. M. McCashland, D. F. Schafer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Hepatitis C (HCV) universally recurs following orthotopic liver transplantation (OLT), representing an important cause for retransplantation. Although it is often treated with interferon and ribavirin, ribavirin is contraindicated in the presence of renal failure. In this setting of renal failure, pegylated-interferon monotherapy may be useful for recurrent HCV in liver transplant patients. Methods: Between June 2001 and November 2002, patients with recurrent HCV were screened to determine if they were eligible for treatment. Renal failure was defined as serum creatinine greater than 1.8 mg/dL. HCVRNA and liver biopsies were performed prior to treatment, end of treatment (EOT) and 6 months after EOT for those who were HCV-RNA negative at EOT. Patients were followed prospectively after starting weekly pegylated-interferon alpha 2b 1.0 μg/kg (Schering-Plough, Kenilworth, NJ, USA). Results: Among the 45 patients with recurrent HCV screened, 9 were eligible, including 8 men and 1 woman of average age 55 years. Eight patients were intolerant to the treatment requiring discontinuation within the first 3 months. Two patients developed a sustained response to HCV eradication. One patient who completed treatment has normal liver tests but is still viremic. Conclusion: Pegylated-interferon alpha 2b is poorly tolerated in liver transplant recipients with recurrent HCV and chronic renal failure. Larger, prospective studies are required to determine the optimum duration of treatment and the impact of treatment on histology and quality of life.

Original languageEnglish
Pages (from-to)1478-1479
Number of pages2
JournalTransplantation Proceedings
Volume35
Issue number4
DOIs
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Hepatitis C
Interferons
Renal Insufficiency
Cohort Studies
Prospective Studies
Liver
Therapeutics
Ribavirin
Transplant Recipients
Liver Transplantation
Chronic Kidney Failure
Creatinine
Histology
Quality of Life
RNA
Transplants
Biopsy
Serum

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure : A prospective cohort study. / Mukherjee, Sandeep; Gilroy, R. K.; McCashland, T. M.; Schafer, D. F.

In: Transplantation Proceedings, Vol. 35, No. 4, 06.2003, p. 1478-1479.

Research output: Contribution to journalArticle

@article{b871b2a9a2ac4c87bb593e0a28c2a656,
title = "Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study",
abstract = "Background: Hepatitis C (HCV) universally recurs following orthotopic liver transplantation (OLT), representing an important cause for retransplantation. Although it is often treated with interferon and ribavirin, ribavirin is contraindicated in the presence of renal failure. In this setting of renal failure, pegylated-interferon monotherapy may be useful for recurrent HCV in liver transplant patients. Methods: Between June 2001 and November 2002, patients with recurrent HCV were screened to determine if they were eligible for treatment. Renal failure was defined as serum creatinine greater than 1.8 mg/dL. HCVRNA and liver biopsies were performed prior to treatment, end of treatment (EOT) and 6 months after EOT for those who were HCV-RNA negative at EOT. Patients were followed prospectively after starting weekly pegylated-interferon alpha 2b 1.0 μg/kg (Schering-Plough, Kenilworth, NJ, USA). Results: Among the 45 patients with recurrent HCV screened, 9 were eligible, including 8 men and 1 woman of average age 55 years. Eight patients were intolerant to the treatment requiring discontinuation within the first 3 months. Two patients developed a sustained response to HCV eradication. One patient who completed treatment has normal liver tests but is still viremic. Conclusion: Pegylated-interferon alpha 2b is poorly tolerated in liver transplant recipients with recurrent HCV and chronic renal failure. Larger, prospective studies are required to determine the optimum duration of treatment and the impact of treatment on histology and quality of life.",
author = "Sandeep Mukherjee and Gilroy, {R. K.} and McCashland, {T. M.} and Schafer, {D. F.}",
year = "2003",
month = "6",
doi = "10.1016/S0041-1345(03)00446-9",
language = "English",
volume = "35",
pages = "1478--1479",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure

T2 - A prospective cohort study

AU - Mukherjee, Sandeep

AU - Gilroy, R. K.

AU - McCashland, T. M.

AU - Schafer, D. F.

PY - 2003/6

Y1 - 2003/6

N2 - Background: Hepatitis C (HCV) universally recurs following orthotopic liver transplantation (OLT), representing an important cause for retransplantation. Although it is often treated with interferon and ribavirin, ribavirin is contraindicated in the presence of renal failure. In this setting of renal failure, pegylated-interferon monotherapy may be useful for recurrent HCV in liver transplant patients. Methods: Between June 2001 and November 2002, patients with recurrent HCV were screened to determine if they were eligible for treatment. Renal failure was defined as serum creatinine greater than 1.8 mg/dL. HCVRNA and liver biopsies were performed prior to treatment, end of treatment (EOT) and 6 months after EOT for those who were HCV-RNA negative at EOT. Patients were followed prospectively after starting weekly pegylated-interferon alpha 2b 1.0 μg/kg (Schering-Plough, Kenilworth, NJ, USA). Results: Among the 45 patients with recurrent HCV screened, 9 were eligible, including 8 men and 1 woman of average age 55 years. Eight patients were intolerant to the treatment requiring discontinuation within the first 3 months. Two patients developed a sustained response to HCV eradication. One patient who completed treatment has normal liver tests but is still viremic. Conclusion: Pegylated-interferon alpha 2b is poorly tolerated in liver transplant recipients with recurrent HCV and chronic renal failure. Larger, prospective studies are required to determine the optimum duration of treatment and the impact of treatment on histology and quality of life.

AB - Background: Hepatitis C (HCV) universally recurs following orthotopic liver transplantation (OLT), representing an important cause for retransplantation. Although it is often treated with interferon and ribavirin, ribavirin is contraindicated in the presence of renal failure. In this setting of renal failure, pegylated-interferon monotherapy may be useful for recurrent HCV in liver transplant patients. Methods: Between June 2001 and November 2002, patients with recurrent HCV were screened to determine if they were eligible for treatment. Renal failure was defined as serum creatinine greater than 1.8 mg/dL. HCVRNA and liver biopsies were performed prior to treatment, end of treatment (EOT) and 6 months after EOT for those who were HCV-RNA negative at EOT. Patients were followed prospectively after starting weekly pegylated-interferon alpha 2b 1.0 μg/kg (Schering-Plough, Kenilworth, NJ, USA). Results: Among the 45 patients with recurrent HCV screened, 9 were eligible, including 8 men and 1 woman of average age 55 years. Eight patients were intolerant to the treatment requiring discontinuation within the first 3 months. Two patients developed a sustained response to HCV eradication. One patient who completed treatment has normal liver tests but is still viremic. Conclusion: Pegylated-interferon alpha 2b is poorly tolerated in liver transplant recipients with recurrent HCV and chronic renal failure. Larger, prospective studies are required to determine the optimum duration of treatment and the impact of treatment on histology and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0038095668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038095668&partnerID=8YFLogxK

U2 - 10.1016/S0041-1345(03)00446-9

DO - 10.1016/S0041-1345(03)00446-9

M3 - Article

C2 - 12826198

AN - SCOPUS:0038095668

VL - 35

SP - 1478

EP - 1479

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -